China
Africa
Explore chapters and articles related to this topic
Use of Dermatologics during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Fourteen observational studies of topical steroid use during pregnancy were reviewed, and included unpublished data from Hungary, Sweden, and other research registries. The European Dermatology Forum Guideline on Topical Corticosteroids in Pregnancy summary of pregnancy outcomes among 1,601,515 women who used topical steroids during the first trimester concluded that the risk of birth defects was not increased (Chi et al., 2017).
Papulosquamous Diseases
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Melek Aslan Kayıran, Jordan V. Wang, Ayşe Serap Karadağ
Topical corticosteroids can reduce inflammation and itching in mild to moderate cases. Antihistamines and moisturizers can also be added. Although these treatments provide symptomatic relief, they do not change the course of the disease.
The Integumentary (Dermatologic) System and Its Disorders
Published in Walter F. Stanaszek, Mary J. Stanaszek, Robert J. Holt, Steven Strauss, Understanding Medical Terms, 2020
Walter F. Stanaszek, Mary J. Stanaszek, Robert J. Holt, Steven Strauss
Several drugs are commonly used in topical or systemic preparations for dermatological conditions. Topical corticosteroids are used in the treatment of atopic eczema, all inflammatory and pruritic eruptions, and hyperplastic and infiltrative disorders. Brief courses of systemic corticosteroids are indicated for severe contact dermatitis.
Local versus Systemic Therapy for Noninfectious Uveitis (NIU)
Published in Seminars in Ophthalmology, 2023
Adverse events (AEs) associated with use of topical steroids include cataract formation, intraocular pressure (IOP) elevation, delayed wound healing, increased risk of infection, ocular surface toxicity, corneal thinning, crystalline keratopathy, eyelid ptosis, pupil dilation, extraocular muscle imbalance, orbital fat atrophy, and systemic glucocorticoid suppression.16 Given these concerns and the susceptibility of children to cataract and IOP complications, chronic use of topical corticosteroids is generally not recommended for the pediatric population.17 However, in a recent retrospective study by Thorne et al., it was demonstrated that that chronic use of topical corticosteroids (specifically prednisolone acetate 1% or rimexolone 1%) in patients with juvenile idiopathic arthritis (JIA) had an 85% lower risk of cataract development at dosing less than or equal to three drops daily compared with greater than three drops daily. The age of patients in this study ranged from 1–36 years old, however it was a predominately pediatric population with a median age of seven.18
Patterns of Non-Infectious Scleritis across a Tertiary Eye Care Network Using the Indigenously Developed Electronic Medical Record System-eyeSmart
Published in Ocular Immunology and Inflammation, 2022
Somasheila I Murthy, Anthony Vipin Das, Priyanka Kammari, Aravind Roy, Soumyava Basu, Merle Fernandes, Varsha M Rathi, Mudit Tyagi
The most common treatment strategy at onset included topical corticosteroid and oral non-steroidal anti-inflammatory drugs in almost similar number of patients, 36.54% and 34.45%, respectively. Oral corticosteroids were started in 19.04% and immunomodulators in 3.54%. These results indicate that at least 70% of patients in our large cohort seemed to present with mild disease and could be managed with topical corticosteroids and oral NSAIDs. These results can be correlated with the relatively low prevalence of systemic disease association that was found in our cohort. Patients with systemic association had a tendency to have more recurrences and are more likely to be started on oral corticosteroids and immunomodulators. In the present study, at least one-third were also on topical corticosteroids, which is different from reported studies. Topical corticosteroids have rarely been used as first-line therapy7,18 with most studies reporting oral NSAID as the first line (ranging from 23 to 81% of patients in various series), followed by oral corticosteroid (12 to 65%) and immunomodulators such as methotrexate and other agents (6.5 to 78%).7–18
Inverse pityriasis rosea secondary to COVID-19 vaccination
Published in Baylor University Medical Center Proceedings, 2022
Blayne Fenner, Jessica L. Marquez, Meredith Pham, Michelle Tarbox
Physical examination revealed erythematous papules and plaques with a trailing scale distributed predominantly in the axilla, inframammary, and groin area, with a total body surface area of around 5% (Figure 1). Dermoscopy revealed a collarette of scale as well as central yellow hue with a peripheral reddish background (Figure 2a). Two 4-mm punch biopsies were performed, one on the first reported lesion under her left breast and the other on a lesion in the groin. Pathology revealed areas of confluent parakeratosis as well as mounds of parakeratosis. Moderate psoriasiform hyperplasia of the epidermis with moderate spongiosis, moderate inflammatory infiltrate of lymphocytes with eosinophils in the dermis, extravasation of red blood cells, and moderate exocytosis of lymphocytes into the epidermis were also observed on histopathology (Figures 2b–2d). A periodic acid-Schiff stain was negative for fungus or yeast. The histologic differential at this point included psoriasis, PR, subacute to chronic eczema, and contact dermatitis. The patient was given topical corticosteroids. Two weeks later, she reported improvement in her symptoms with almost complete resolution of the rash and pruritus.